VivoSeq
Oncology

CNS Tumors

0

Pipeline Programs↗

2

Active Trials↗

1

Companies Involved↗

CNS Tumors is an early-stage landscape with 0 programs across 1 company. The most active players are Amgen.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

86/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed6 · 67%
Recruiting2 · 22%
Withdrawn1 · 11%

Clinical Trials

Trial Activity

9 trials

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors
Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06528691·52 enrolled
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Recruiting·NNationwide Children's Hospital·Phase 1/2·NCT05278208·65 enrolled
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
Completed·BBlaze Bioscience Inc.·Phase 1·NCT02462629·29 enrolled
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00025675·105 enrolled
A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors
Completed·UUniversity of New Mexico·Phase 1·NCT00251797·10 enrolled
Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors
Completed·Amgen logoAmgen·Phase 1·NCT02756845·15 enrolled
Study of Tozuleristide and the Canvas Imaging System in Pediatric Subjects With CNS Tumors Undergoing Surgery
Completed·BBlaze Bioscience Inc.·Phase 2/3·NCT03579602·118 enrolled
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors
Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT01505569·44 enrolled
MRI Gadopiclenol Enhanced Imaging of CNS Tumors
Withdrawn·MMedical University of South Carolina·N/A·NCT06127810

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)